protein tyrosine kinase inhibitors (Cotinga Pharmaceuticals)

N/A

Report date: 2025/06/11 11:28:20
NME

Base Information

Drug Nameprotein tyrosine kinase inhibitors (Cotinga Pharmaceuticals)
Drug Alias Nameprotein tyrosine kinase inhibitors (Critical Outcome Technologies)COTI-001COTI-003ECOTI-002
ClassificationSmall molecules
Mechanisms of ActionTyrosine-protein kinase receptor FLT3 inhibitorsAnticancer protein kinase inhibitors
TargetsTyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCotinga Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesCotinga Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A